A Trial to Evaluate the Safety and Tolerability of DV700P-RNA and DV701B1.1-RNA Immunization in Combination With Antiretroviral Analytical Treatment Interruption (ATI) in People Living With HIV for Elicitation of V3-glycan Antibodies
Public ClinicalTrials.gov record NCT07569029. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Nonrandomized Phase 1 Clinical Trial to Evaluate the Safety and Tolerability of DV700P-RNA and DV701B1.1-RNA Immunization in Combination With Antiretroviral Analytical Treatment Interruption (ATI) in People Living With HIV for Elicitation of V3-glycan Antibodies
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This phase 1 study will evaluate the safety, tolerability, and immune responses of two experimental mRNA HIV vaccines in adults living with HIV who are in overall good health. The study will enroll about 42 participants at multiple study sites. Researchers will assess whether these vaccines can start or strengthen antibody responses against HIV. The study will also evaluate how a closely monitored planned pause in antiretroviral therapy affects these immune responses.
Study identification
- NCT ID
- NCT07569029
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 42 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 60 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 14, 2026
- Primary completion
- Aug 30, 2027
- Completion
- Aug 30, 2027
- Last update posted
- Aug 16, 2026
2026 – 2027
United States locations
- U.S. sites
- 12
- U.S. states
- 8
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Alabama CRS (Site ID: 31788) | Birmingham | Alabama | 35222 | Recruiting |
| Bridge HIV CRS (Site#: 30305) | San Francisco | California | 94102 | Not yet recruiting |
| The Ponce de Leon Center CRS (Site ID: 5802) | Atlanta | Georgia | 30308 | Recruiting |
| The Hope Clinic of the Emory Vaccine Center CRS (Site #: 31440) | Decatur | Georgia | 30030 | Not yet recruiting |
| Beth Israel Deaconess Medical Center / BIDMC VCRS (Site ID: 32077) | Boston | Massachusetts | 02115 | Recruiting |
| Brigham and Women's Hospital Vaccine CRS (BWH VCRS) (Site#: 30007) | Boston | Massachusetts | 02115 | Not yet recruiting |
| Columbia P&S CRS (Site#: 30329) | New York | New York | 10032 | Not yet recruiting |
| University of Rochester Vaccines to Prevent HIV Infection CRS (Site#: 31467) | Rochester | New York | 14642 | Not yet recruiting |
| Penn Prevention CRS (Site#: 30310) | Philadelphia | Pennsylvania | 19104 | Not yet recruiting |
| University of Pittsburgh CRS (Site#: 1001) | Pittsburgh | Pennsylvania | 15213 | Not yet recruiting |
| Houston Advancing Research Team CRS (Site # 31473) | Houston | Texas | 77030-1501 | Not yet recruiting |
| Seattle Vaccine and Prevention CRS (Site ID: 30331) | Seattle | Washington | 98109 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 7 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07569029, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 16, 2026 · Synced Sep 3, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07569029 live on ClinicalTrials.gov.